LONDON (Alliance News) - Tiziana Life Sciences PLC Monday outlined its plan for further development of foralumab, the company's fully human anti-CD3 antibody.
The biotechnology company focused on targeted drugs to treat diseases in oncology and immunology said it will evaluate foralumab with the addition of two key individuals, professors Kevan Herold and Howard Weiner, which will both join the company's scientific advisory board.
Initially, the company will focus on foralumab in two clinical applications: graft versus host disease and ulcerative colitis.
Graft versus host disease is a possible complication of high dose cancer treatment that happens after a bone marrow or stem cell transplant from another person, whilst ulcerative colitis is an inflammatory bowel disease.
"The addition of professors Herold and Weiner to Tiziana's scientific advisory board marks a vital step for the company," said Gabriele Cerrone, executive chairman.
"Proffesor Herold's previous experience in CD3 antibody research will be invaluable in planning the clinical strategy for foralumab, and he will take on a major role in its further development. In addition, Professor Weiner brings a wealth of expertise in the field of immunology and regulation of processes that govern cancer and autoimmune disease, which will also be critical as we build out our anti-CD3 clinical strategy and the development of our fully human antibody asset, foralumab," Cerrone added.
Tiziana shares were trading down 2.5% to 204.75 pence per share on Monday morning.
By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
